VISTA-Mediated Immune Evasion in Cancer: Protein and Assay Selection

VISTA-mediated immune evasion in cancer helps create an immunosuppressive tumor microenvironment in which T-cell activation and antitumor immunity may be reduced. Researchers studying this pathway need recombinant VISTA proteins that match their assay format, capture strategy, target sequence, tag and activity requirements.

Beta LifeScience provides active human VISTA protein in Fc-tagged and site-specifically biotinylated Avi-tagged formats. These proteins support antibody screening, ELISA development, binding analysis and immune-checkpoint research when matched to the appropriate capture and detection strategy. View Active Human VISTA Protein | View Biotinylated Human VISTA Protein

What Is VISTA-Mediated Immune Evasion?

VISTA, also called VSIR, B7-H5, PD-1H, Gi24 and C10orf54, is an inhibitory immune checkpoint involved in immune tolerance and the regulation of T-cell responses.

Within the tumor microenvironment, VISTA activity can contribute to immune evasion by:

• Limiting T-cell activation
• Supporting T-cell suppression
• Influencing myeloid-cell activity
• Maintaining immune tolerance
• Reducing effective antitumor responses
• Supporting suppressive immune-cell states

VISTA-mediated immune evasion helps tumors maintain an immunosuppressive environment in which T-cell activation and antitumor immunity may be reduced. Its association with myeloid cells, naïve T cells and regulatory T cells makes VISTA relevant to both innate and adaptive tumor immunity.

Why Is VISTA Important in Cancer Research?

The tumor microenvironment contains cancer cells, stromal components, immune cells and soluble factors that collectively shape tumor immunity. Local metabolic conditions, including extracellular acidity, can also influence immune-checkpoint activity. VISTA has a reported pH-dependent interaction with PSGL-1. Primary research published in Nature found that VISTA selectively engages PSGL-1 and suppresses T cells under acidic conditions resembling those found in tumors. This offers a potential mechanism through which the acidic tumor microenvironment supports immune suppression. 

Researchers study the VISTA immune checkpoint to investigate:

• T-cell activation and suppression
• Myeloid-cell regulation
• Regulatory T-cell activity
• Immune tolerance
• VISTA–ligand binding
• Checkpoint-blocking antibodies
• Tumor-associated immune suppression
• Combination strategies involving PD-1, PD-L1 or CTLA-4
• Potential resistance mechanisms in immuno-oncology research

Assay conditions should be selected according to the biological interaction being studied. An acidic condition may be relevant for VISTA–PSGL-1 research, while other VISTA assays may require different conditions and controls.

VISTA, PD-1, PD-L1 and CTLA-4 Research Options

VISTA, PD-1, PD-L1 and CTLA-4 all regulate immune activity, but they have different expression patterns and biological functions. Comparing these targets can help researchers select proteins for individual or combination checkpoint studies.

PD-1 is an inhibitory receptor commonly associated with activated or dysfunctional T cells. PD-L1 is one of its principal ligands. CTLA-4 regulates T-cell costimulation, while VISTA is strongly associated with myeloid regulation, immune tolerance and T-cell quiescence. These differences make VISTA a valuable target for immune-evasion research that may not be fully explained by PD-1, PD-L1 or CTLA-4 alone.

Browse Immune Checkpoint Proteins

Why Study VISTA as a Cancer Immunotherapy Target?

VISTA is being investigated as a cancer immunotherapy target because its immune-regulatory activity differs from established checkpoint pathways.

Relevant research areas include:

• VISTA-blocking antibody discovery
• Antibody affinity and specificity screening
• VISTA–ligand interaction studies
• T-cell functional assays
• Myeloid-cell biology
• Tumor-microenvironment modeling
• Combination checkpoint research
• Mechanisms associated with immune-checkpoint resistance

VISTA-targeting agents remain an active area of preclinical and clinical research. Recombinant VISTA proteins are research reagents and do not provide evidence of clinical safety or therapeutic efficacy.

Compare Active Human VISTA Protein Formats

The most suitable VISTA protein depends on how the molecule will be immobilized, captured 

Both products use a mammalian HEK293 expression system and contain the human VISTA extracellular region from Phe33 to Ala194. The main purchasing decision is therefore the tag and immobilization strategy.

Compare Product Specifications | Ask About Pack Sizes

Fc-Tagged or Biotinylated VISTA: Which Format Should You Choose?

Choose Fc-tagged VISTA for Fc-compatible workflows.

The active Fc-tagged human VISTA protein is suitable when the assay uses protein A/G, anti-Fc detection or another Fc-compatible capture strategy.

The product page documents:

• ELISA quality-control activity
• SPR data generated using a Biacore T200
• Greater than 95% purity
• HEK293 expression
• Less than 1 EU/µg endotoxin

Researchers should include Fc-only or unrelated Fc-fusion controls when the detection system could recognize the Fc domain.

Choose biotinylated VISTA for streptavidin-based capture.

The biotinylated human VISTA protein contains C-terminal His and Avi tags. Site-specific AviTag biotinylation supports controlled capture on streptavidin-coated plates or compatible biosensors.

This format can be considered for:

• Streptavidin-based ELISA
• Antibody screening
• Biotin-dependent pull-down assays
• Streptavidin biosensors
• Oriented surface immobilization
• Binding-assay development

The product page documents ELISA activity using immobilized biotinylated human B7-H5 on a streptavidin-coated plate. Researchers should confirm that the tag, coating density and detection antibody fit their assay design.

Related purchasing options include Biotinylated Proteins and Avi-Tagged Proteins.

Choose VISTA Protein by Application

Antibody screening and ELISA

Recombinant VISTA can support antibody binding and concentration-response experiments. Include blank, negative-protein and tag controls to separate target binding from detection-system background.

SPR and BLI binding analysis

SPR and BLI can evaluate interaction kinetics between VISTA and antibody candidates or binding partners. The selected protein format should fit the biosensor or chip chemistry without masking the relevant binding site.

Cell-based VISTA research

Cellular experiments may measure T-cell activation, proliferation or cytokine production. If the model includes an acidic tumor microenvironment, cell viability and matched pH controls should be included. Product endotoxin and formulation should also be reviewed before cell-based use.

Commercial VISTA Protein Selection Checklist

Before purchasing, also determine whether one lot must support an extended study. Researchers can ask about bulk quantities, lot availability and repeat-production options through Technical Support.

When Should You Request Custom VISTA Protein Production?

Catalog products are suitable when the human extracellular sequence, HEK293 expression system and available Fc or His-Avi formats match the workflow.

Custom Protein Expression is appropriate when a project requires:

• Another species or sequence variant
• Different domain boundaries
• An alternative purification tag
• Tag removal
• Custom biotinylation
• Lower endotoxin
• A specific buffer or concentration
• Liquid rather than lyophilized material
• A larger production quantity

Beta LifeScience’s service page lists one-stop support from gene synthesis through protein expression and purification, bacterial, yeast, insect and mammalian platforms, and custom production from milligram to gram scale depending on the target and expression results. Custom sequence, tag, formulation and endotoxin requirements can be discussed during technical evaluation.

The service page also publishes a “No proteins, no payment” guarantee. The exact conditions and project eligibility for this guarantee should be confirmed in the written quotation before production begins. Pricing and timeline depend on the construct, expression platform, required yield, purification strategy, formulation and quality-control requirements.

Submit a Project Evaluation | Review Custom Protein Expression

Start Your VISTA Immune-Checkpoint Research

VISTA-mediated immune evasion connects myeloid regulation, T-cell suppression, regulatory T cells, immune tolerance and the tumor microenvironment. Selecting the correct recombinant protein format allows researchers to match VISTA to the intended ELISA, SPR, BLI or antibody-screening workflow.

Beta LifeScience offers active Fc-tagged and site-specifically biotinylated human VISTA proteins, along with custom-expression options for specialized constructs and production requirements. Check Fc-Tagged VISTA Availability | Check Biotinylated VISTA Availability | How to Order

FAQs

What is the VISTA immune checkpoint?

VISTA is an inhibitory immune checkpoint protein associated with T-cell regulation, myeloid cells and immune tolerance. It is also known as VSIR, B7-H5, PD-1H, Gi24 and C10orf54.

How does VISTA support immune evasion?

VISTA can help maintain an immunosuppressive tumor microenvironment by limiting T-cell activation and supporting immune-regulatory conditions. Its pH-sensitive interaction with PSGL-1 is particularly relevant to acidic tumor environments.

Is VISTA the same as PD-1 or PD-L1?

No. VISTA, PD-1 and PD-L1 are distinct immune-checkpoint molecules with different expression patterns and regulatory mechanisms. They can be studied together in combination checkpoint research.

Which VISTA protein should I select for ELISA?

Choose according to the plate-capture strategy. Fc-tagged VISTA can support Fc-compatible workflows, while biotinylated VISTA supports streptavidin-based immobilization. Both product pages provide documented ELISA activity.

Is recombinant VISTA a cancer treatment?

No. Recombinant VISTA proteins are research-use reagents. VISTA remains an investigational cancer-immunotherapy target.